



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Amphetamine Products Page: 1 of 4

Effective Date: 12/16/2022 Last Review Date: 3/2022

Applies to: Illinois Florida Florida Kids
 New Jersey Maryland Michigan
 Pennsylvania Kids Virginia

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for amphetamine products under the member's prescription drug benefit.

Description:

Adderall

Adderall is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) and Narcolepsy.

Adderall XR

Adderall XR is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD).

Adzenys ER, Adzenys XR-ODT, Desoxyn, Dyanavel XR

These products are indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

Dexedrine

Narcolepsy

Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome.

Dextroamphetamine, ProCentra, Zenzedi

Narcolepsy

Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.

Evekeo

Narcolepsy

Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Amphetamine Products Page: 2 of 4

Effective Date: 12/16/2022 Last Review Date: 3/2022

Applies to: Illinois Florida Florida Kids
 New Jersey Maryland Michigan
 Pennsylvania Kids Virginia

of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.

Exogenous Obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction for patients refractory to alternative therapy, e.g., repeated diets, group programs, and other drugs. The limited usefulness of amphetamines should be weighed against possible risks inherent in use of the drug.

Evekeo ODT

Evekeo ODT is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in pediatric patients 3 to 17 years of age.

Mydayis

Mydayis is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older.

Xelstrym

Xelstrym is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

Compendial Uses

Narcolepsy

Applicable Drug List:

Amphetamine/dextroamphetamine

Dextroamphetamine

Procentra

Policy/Guideline:

The requested drug will be covered with prior authorization when the following criteria are met:

- The patient has a diagnosis of Attention-Deficit Hyperactivity Disorder (ADHD) or Attention-Deficit Disorder (ADD)
AND
- If 5 years of age or younger, the patient continues to have Attention-Deficit Hyperactivity Disorder (ADHD) or Attention-Deficit Disorder (ADD) symptoms despite participating in evidence-based behavioral therapy (e.g., parent training in behavior management (PTBM), behavioral classroom interventions)

AND



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name:	Amphetamine Products	Page:	3 of 4
Effective Date:	12/16/2022	Last Review Date:	3/2022
Applies to:	<input type="checkbox"/> Illinois <input checked="" type="checkbox"/> New Jersey <input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Florida <input type="checkbox"/> Maryland <input type="checkbox"/> Virginia	<input checked="" type="checkbox"/> Florida Kids <input type="checkbox"/> Michigan

- The diagnosis has been appropriately documented (e.g., evaluated by a complete clinical assessment, using DSM-5, standardized rating scales, interviews/questionnaires)

OR

- The patient has the diagnosis of narcolepsy

AND

- The diagnosis has been confirmed by a sleep study

Approval Duration and Quantity Restrictions:

Approval:

Attention-Deficit Hyperactivity Disorder (ADHD) or Attention-Deficit Disorder (ADD):

Approve 12 months

Narcolepsy: Approve 12 months

Quantity Level Limit: Reference Formulary for drug specific quantity level limits

References:

1. Adderall [package insert]. Parsippany, NJ: Teva Pharmaceuticals USA; March 2020.
2. Adderall XR [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; August 2020.
3. Adzenys ER [package insert]. Grand Prairie, TX: Neos Therapeutics, Inc.; September 2017.
4. Adzenys XR-ODT [package insert]. Grand Prairie, TX: Neos Therapeutics, Inc.; February 2018.
5. Desoxyn [package insert]. Bristol TN: UPM Pharmaceuticals; March 2019.
6. Dexedrine Spansule [package insert]. Winchester, KY: Catalent Pharma Solutions; March 2019.
7. Dextroamphetamine sulfate [package insert]. Atlanta, GA: Wilshire Pharmaceuticals, Inc.; June 2021.
8. Dyanavel XR [package insert]. Monmouth Junction, NJ: Tris Pharma, Inc.; November 2021.
9. Evekeo [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; October 2019.
10. Evekeo ODT [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; April 2021.
11. Mydayis [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; August 2020.
12. ProCentra [package insert]. Newport, KY: Independence Pharmaceuticals, LLC; February 2017.
13. Vyvanse [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; July 2021.
14. Xelstrym [package insert]. Jersey City, NJ: Noven Therapeutics, LLC; March 2022.
15. Zenedi [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; October 2019.
16. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2021; Accessed November 1, 2021.
17. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com>. Accessed November 1, 2021.



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Amphetamine Products Page: 4 of 4

Effective Date: 12/16/2022 Last Review Date: 3/2022

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	

18. Morgenthaler TI, Vishesh KK, Brown T, et al. Practice Parameters for the Treatment of Narcolepsy and other Hypersomnias of Central Origin. *Sleep* 2007;30(12):1705-11.
19. Wolraich ML, Hagan JF, Allan C, et al. AAP Subcommittee On Children And Adolescents With Attention-Deficit/Hyperactive Disorder. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. *Pediatrics*. 2019;144(4):e20192528.
20. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013. <https://dsm.psychiatryonline.org>.
21. FDA Drug Safety Communication. Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults. <http://www.fda.gov/Drugs/DrugSafety/ucm277770.htm>.
22. Krahn LE, Hershner S, Loeding LD, et al. Quality Measures for the Care of Patients with Narcolepsy. *J Clin Sleep Med* 2015; 11(3): 335-355.